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Abstract
Medical research institutions have generated massive amounts of biological data by
genetically profiling hundreds of cancer cell lines. In parallel, academic biology labs
have conducted genetic screens on small numbers of cancer cell lines under custom ex-
perimental conditions. In order to share information between these two approaches to
scientific discovery, this article proposes a “frequentist assisted by Bayes” (FAB) pro-
cedure for hypothesis testing that allows historical information from massive genomics
datasets to increase the power of hypothesis tests in specialized studies. The exchange
of information takes place through a novel probability model for multimodal genomics
data, which distills historical information pertaining to cancer cell lines and genes across
a wide variety of experimental contexts. If the relevance of the historical information
for a given study is high, then the resulting FAB tests can be more powerful than the
corresponding classical tests. If the relevance is low, then the FAB tests yield as many
discoveries as the classical tests. Simulations and practical investigations demonstrate
that the FAB testing procedure can increase the number of effects discovered in ge-
nomics studies while still maintaining strict control of type I error and false discovery
rates.
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1 Introduction
In recent years, non-profit research organizations have initiated large-scale efforts to create
genetic maps of cancer (Tsherniak and others , 2017; Meyers and others , 2017; McFarland
and others , 2018; Iorio and others , 2016; Behan and others , 2019; Ghandi and others , 2019).
The data produced by these projects measure different modalities of the cancer genome.
For instance, RNAseq data measure how much RNA is being expressed from a particular
gene in a given cancer cell line. CRISPR dependency data measure the extent to which the
proliferation of a cancer cell line is affected upon deletion of a given gene. DNA sequencing
data record the presence or absence of aberrant nucleotide sequences in the coding regions
of genes in cancer cell lines.
The purpose of exploratory data-driven screens like these is to discover patterns in the
relationships among cancer cell lines and among genes, patterns which will hopefully yield
new biological insights. However, many biological questions cannot be answered without
hypothesis-driven experiments, which complement the scattershot approach of data-driven
screens by testing the effects of targeted interventions on the baseline state of cellular models
of cancer. For example, the CRISPR-Cas9 gene editing technology has been used in con-
junction with traditional treatment-control experimental designs to successfully uncover and
validate the functional role of several genes (Kory and others , 2018; Birsoy and others , 2015;
Pusapati and others , 2018; Liao and others , 2017).
An open question in modern biology is how to properly inform hypothesis-driven exper-
imenters with the information available in massive genomics datasets created by data-driven
screens. The most conspicuous efforts to deliver genomics information to biologists come in
the form of online data portals. Online portals allow biologists to browse and visualize a
corpus of publicly available genomics data without the need for computing expertise. For
this reason, portals are invaluable tools for strengthening biological arguments, sleuthing in
an ad-hoc manner to find connections to genetic mechanisms of interest, and generating new
hypotheses. However, data portals do not provide a method for directly incorporating infor-
mation from the corpus into the statistical evaluation of new hypotheses. Modern statistical
methods applicable to analyzing large genomics datasets are also potentially ill-suited to the
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needs of hypothesis-driven experiments. While the technologies and methodologies employed
by a modern working biologist are complex, the statistical tests necessary to extract insights
from their data need not be.
The current state of affairs in biology therefore demands a framework for (1) distilling
information from a corpus of multimodal genomics data, (2) quantifying the relevance of
this information to specific hypothesis-driven experiments, and (3) incorporating relevant
information from the corpus into statistical evaluations of specific experimental hypotheses,
while maintaining error rate controls. This article proposes such a framework that combines
the flexibility of Bayesian statistical modeling with the statistical guarantees of frequentist
hypothesis testing procedures. Specifically, the proposal is to first distill information from a
historical corpus with a probabilistic tensor factorization model, which quantifies the relation-
ships among a set of biological entities measured by different genomics modalities. Inference
from this tensor probability model creates a numerical feature profile for each entity, which
encodes historical information distilled from all modalities. Next, an empirical Bayes proce-
dure is used to assess the relevance of these features to data from a new hypothesis-driven
study. Finally, the relevant information is used to construct hypothesis tests and p-values
for biological effects measured by the new experiment. This is accomplished by using the
recently-developed “frequentist, assisted by Bayes” (FAB) hypothesis testing framework de-
scribed by Hoff (2019), which is based on frequentist testing procedures that are optimal with
respect to historical information. As a result, if the historical information is highly relevant
to the new experimental data, the FAB tests will have higher power than the corresponding
classical tests that do not make use of historical information. Conversely, the proposed em-
pirical Bayes procedure generates FAB tests whose power approaches that of classical tests
when the historical information is irrelevant. The FAB tests retain type I error rate and false
discovery rate (FDR) guarantees whether or not the historical information is relevant to the
new modality in the study at hand. Hence, the FAB testing procedure described here may
be applied with confidence to studies performed with any number of measurement types or
experimental designs, even when the utility of the historical information is unknown.
The remainder of the article is organized as follows: Section 2.1 describes the FAB
testing procedure in the context of hypothesis-driven genomics experiments where histori-
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cal information is available for multiple biological effects. Section 2.2 presents an empirical
Bayes method for quantifying the relevance of the historical information to a new set of
experimental data. Section 2.3 details the probabilistic model for distilling information from
multimodal genomics datasets, which makes the FAB procedure applicable to practical set-
tings where historical information for the biological effects under study is not otherwise
available. Finally, Sections 3.1 and 3.2 describe results from the application of the FAB tests
to simulated and real datasets. The simulation studies in Section 3.1 empirically validate
the FAB procedure’s theoretical type I error properties under null scenarios and showcase its
type II behavior under non-null scenarios. Section 3.2 presents a comprehensive catalogue of
practical settings in which the FAB procedure can be used to discover more biological effects
than the classical procedure. The examples presented include CRISPR screens, cell viabil-
ity profiling for drug repurposing, differential expression analysis, differential dependency
analysis, and modifier screens targeted towards specific genetic interactions.
2 Methods
Advances in modern sequencing technologies have dramatically increased the amount of data
produced in hypothesis-driven biological experiments. Analysis of data from such experi-
ments may involve hundreds or thousands of statistical hypothesis tests, each corresponding
to a biological effect of interest. The following sections describe a procedure by which the
presence of multiple hypotheses, often a statistical challenge in the analysis of genomics
data, creates an opportunity for increasing the power of hypothesis tests by using historical
information. The testing procedure described maintains frequentist type I error guarantees
and adaptively estimates the relevance of the historical information to a new set of experi-
mental data so that type II error approaches that of classical tests when the relevance of the
historical information is low. When historical information for each of thousands of biological
effects under investigation in a particular study is not readily available, a generalization of
the probability model underlying the testing procedure may be used to distill that informa-
tion from multimodal genomics data. The result is a two-stage estimation procedure, which
has the potential to increase the number of discoveries made in a wide variety of genomics
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studies.
2.1 FAB hypothesis tests for genomics data
Hypothesis-driven genomics experiments are often designed to evaluate a null hypothesis
Hj : θj = 0 for each of many biological effects θj, j = 1, . . . ,M . In many cases, the data
used to evaluate these hypotheses consist of independent, approximately normally distributed
estimates θˆ1, . . . , θˆM of the effects θ1, . . . , θM , as well as an estimate of the variance of each
θˆj. Specifically, it is often assumed that
θˆj ∼ N(θj, σ2j/cj) (1)
independently for j = 1, . . . ,M , where each cj is a known constant. Given an estimator σˆ
2
j of
σ2j , the statistic Tj =
√
cj θˆj/σˆj has approximately a standard normal or t-distribution under
the null hypothesis Hj : θj = 0. In what follows, t-distributions are assumed as these are
exact in several cases. For example, if the data for effect j consist of a sample Y1j, . . . , Ynj ∼
i.i.d. N(θj, σ
2
j ), then setting θˆj to be the sample mean, σˆ
2
j to be the the pooled sample
estimate of σ2j , and cj = nj, each Tj is exactly t-distributed under the hypothesis Hj.
Under this sampling model, the statistical significance of the effect θj is typically eval-
uated using a classical two-tailed t-test, which tests Hj : θj = 0 versus Kj : θj 6= 0. With
some algebraic manipulations, it can be shown that the p-value for the two-tailed t-test has
the following form:
pj = 1− |Fν(Tj)− Fν(−Tj)| (2)
where Tj =
√
cj θˆj/σˆj, Fν is the cumulative distribution function of the t-distribution with ν
degrees of freedom, and σˆj
2 is an estimator of σ2j for which νσˆj
2/σ2j ∼ χ2ν . Under the null
hypothesis Hj, pj is uniformly distributed in the interval (0, 1), so the type I error rate of
the test may be controlled at level α by rejecting the null when pj < α.
A useful mathematical fact first noted by Hoff (2019) is that for any value of bj, the
following quantity is also uniformly distributed under Hj:
pFABj = 1− |Fν (Tj + bj)− Fν (−Tj)| . (3)
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Hypothesis tests based on pFABj therefore have the same type I error rates as those based
on the classical p-value. However, under an alternative value of θj with the same sign as
bj, p
FAB
j will be stochastically smaller than pj. Therefore, careful selection of bj can lead to
a more powerful hypothesis test than the classical two-sided t-test. If θj is positive, then
the FAB p-value approaches the p-value from a one-sided test against the alternative θj > 0
as bj → ∞. Likewise, if θj is negative, the FAB p-value approches that of a one-sided test
against the alternative θj < 0 as bj → −∞. The FAB p-value can therefore be as small as
half the classical p-value. However, the FAB p-value can be larger than the classical p-value
for values of θj and bj with opposite sign.
A principled approach to using historical data to inform the choice of bj is to encode
information about θj with a prior distribution, say θj ∼ N(mj, vj). Here, the quantities mj
and vj are historically-informed location and scale parameters for the biological effect θj. As
shown in Hoff (2019), if σ2j were known, the value of bj that maximizes the prior expected
power of any test based on pFABj is
bOPTj = 2mjσj/
√
cjvj. (4)
In practice, σ2j is not known and so must be replaced with an estimator, in which case the
corresponding value of bj is only approximately (asymptotically) optimal, in terms of prior
expected power.
2.2 Assessing relevance of historical information
As discussed in Hoff (2019), the uniformity of pFAB under Hj is guaranteed regardless of
the choice of prior distribution as long as the information used to compute bj is statistically
independent of Tj. The choice of prior parameters mj, vj must therefore be informed by
quantities that are independent of the data used to compute Tj. In the setting of multiple
biological hypotheses, such indirect information can be extracted by a probability model
that describes the relationships among the biological effects θj, j = 1, . . . ,M . The method
discussed here models these relationships as a function of historical information while using
an empirical Bayes strategy to determine the relevance of that information to the current
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experimental data.
Specifically, let the data from a hypothesis-driven experiment be summarised by vec-
tors Y¯,S ∈ RM , where entries Y¯j and Sj denote the sample means and sample standard
deviations, respectively, of measurements made on θj across nj replicates. Further, suppose
that historical information about each biological effect θj is available in the form of a vector
of q features derived from a large corpus of genomics data and that these vectors are collected
into the rows of a matrix X ∈ RM×q. Then the experimental data and the biological effects
can be jointly described by a sampling model for the observed data
Y¯|θ ∼ NM
(
θ, diag(σ21/n1, . . . , σ
2
M/nM)
)
, (5)
and a model relating the unobserved biological effects to the explanatory variables X,
θ|β ∼ NM(Xβ, τ 2IM). (6)
Together, these two models are sometimes referred to as the Fay-Herriot model (Fay and
Herriot, 1979; Ghosh and Rao, 1994), a type of hierarchical model used in the small-area
estimation literature. The model (6) for the parameters is referred to as the linking model, as
it relates the effects of interest to historical effect-level information X through the parameter
β. The parameter τ 2 describes the magnitude of the variation in the biological effects that
cannot be explained by X. The magnitude of β relative to τ 2 is a measure of the relevance
of the historical data to the hypothesis-driven experiment that generates Y¯ and S.
To quantify the relevance of the historical information, an empirical Bayes strategy is
adopted by placing the hierarchical prior distribution
β ∼ Nq
(
0, ψ2Iq
)
(7)
on the parameter β from the linking model (6). If the variance parameters σ2, τ 2 and ψ2 are
known, then the induced conditional distribution of θj given all of the experimental data not
corresponding to Hj is normal and can be written in closed form. The mean and variance
of this distribution θj|Y¯−j are then natural choices for the prior parameters mj and vj. The
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form of these quantities is given by the following expressions
m˜j = X
>
j G
−1
−jX
>
−jY¯−j v˜j =
(
Wjj
Wjj + τ 2
)2
X>j G
−1
−jXj + τ
2. (8)
where G−j = X>−jH
−1
−jX−j + (1/ψ
2)Iq, H = τ
2IM + W, W = diag(σ
2
1/n1, . . . , σ
2
M/nM), and
Xj denotes the column vector containing the entries of the j
th row of X. Given a suitable es-
timator σ˜2j that is independent of σˆ
2
j , data-derived plug-in estimators for τ
2, ψ2 are obtained
by maximizing the marginal likelihood of the data under a pooled variance approximation
(see Section 1.1 of the Appendix). From (26) it is clear that when the historical information
is not relevant to the experimental data—i.e. τ 2/ψ2 is large—prior uncertainty about θj is
correspondingly large, and the prior mean of θj is close to zero. Conversely, when τ
2/ψ2 is
small, the prior mean and variance of θj are close to those implied by the least squares esti-
mator of β under the weighted regression model Y¯ ∼ NM(Xβ,W), in which the biological
effects are exactly a linear combination of the columns of X.
The procedure above ensures that the prior distribution on each biological effect is
strong only when the historical information is relevant to the current experimental data.
Hence, the quantity
bFABj = 2m˜jσ˜j/
√
nj v˜j (9)
tends to have a large absolute value only when the relevance of the historical information is
high. Since bFABj is statistically independent of Tj, Hj can be evaluated with p
FAB
j by setting
bj := b
FAB
j in (3). This yields a FAB test that has the same power as the classical test if the
prior information is irrelevant—i.e. as bFABj → 0. However, the FAB test is more powerful
than the classical test if the prior information is accurate. Importantly, though, the FAB
p-value is uniformly distributed under the null hypothesis regardless of the form or accuracy
of the linking model in (6). The validity of the FAB test, like that of the classical test, relies
only on the validity of the sampling model in (5).
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2.3 Distilled historical information
The FAB testing procedure described above relies upon historical information pertaining to
biological effects θj for j = 1, . . . ,M . Because of the utility of cancer cell lines as model or-
ganisms for the study of human genomics, a vast body of genomics studies—diverse in terms
of methodology, technology, and motivating research question—concern biological effects of
the type θj = θlgk, where l corresponds to a particular cancer cell line, g corresponds to a
particular gene, and k corresponds to a genomics modality. Given a matrix X of historical
features describing associations among cancer cell lines and among genes, the FAB testing
procedure would be applicable to any study that produces measurements involving these
entities. However, if the information in X is to be relevant to many future studies, the
relationships captured by the historical features must generalize beyond any one particular
modality.
Cancer genomics data corpora represent estimates of biological effects θlgk from several
modalities such as RNA sequencing, DNA sequencing, CRISPR dependency, and others.
Features for cancer cell lines and genes that are expressive enough to capture the structure
uncovered by all of these screening modalities have the potential to be sufficiently general
to be useful for FAB testing in future genomics studies. Suppose that the biological effects
measured in a collection of cancer genomics data with L cancer cell lines, G genes, and K
modalities are represented by a three-way tensor Θ with entries θlgk. Then a low rank tensor
approximation to Θ can be made, so that
θlgk ≈ µk + U>l BkVg (10)
where Ul ∈ RdU ,Vg ∈ RdV ,Bk ∈ RdU×dV , and dU and dV are much smaller than L and G,
respectively. The approximation above forms the basis of a statistical model
θlgk|Bk,Ul,Vg, µk, τ 2k ∼ N
(
µk + U
>
l BkVg, τ
2
k
)
(11)
in which the model parameters consist of a matrix U containing dU -dimensional vector repre-
sentations of cancer cell lines, a matrix V containing dV -dimensional vector representations
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of genes, and a tensor B, which modulates the inner product between these representations.
In contrast to a modality-wise tensor SVD model, in which Θk ≈ UkBkV>k for each modal-
ity slice, the features in U and V are global, i.e. constant across experimental modalities.
This form allows information to be shared across the different Θk so that U and V encode
information from all experimental modalities, while each matrix slice Bk selects the features
of U and V local to modality k.
Authors Ye (2005), Sutskever and others (2009), and Khan and Kaski (2014) consider
similar models for tensor data. The probabilistic framework proposed here extends their
approaches to accommodate characteristics typical of genomics datasets. For instance, for
many such datasets, it is desirable to work with data values Ylgk that reflect an estimate
of θlgk after several processing and cleaning steps have been applied to raw measurement
values. For continuous-valued Ylgk, the normal model (11) can be used by setting Ylgk = θlgk,
so that marginally
Ylgk|Bk,Ul,Vg, µk, τ 2k ∼ N
(
µk + U
>
l BkVg, τ
2
k
)
(12)
If instead the data corresponding to effects Θk are binary mutation calls, the latent variable
model of Albert and Chib (1993) can be adapted to the tensor model, such that marginally
over θlgk the tensor data entries Ylgk follow a Bernoulli distribution with success probability
depending on the variables Ul, Vg, and Bk:
Ylgk =
 1, if θlgk > 00, if θlgk < 0
θlgk|Bk,Ul,Vg, µk ∼ N
(
µk + U
>
l BkVg, 1
)
.
(13)
For data that are strictly positive and continuous—as found in RNA sequencing datasets—
the “tobit” model (Chib, 1992) can be used, again letting data Ylgk be a deterministic function
of θlgk:
Ylgk =
 θlgk, if θlgk > 00, if θlgk < 0
θlgk|Bk,Ul,Vg, µk, τ 2k ∼ N
(
µk + U
>
l BkVg, τ
2
k
)
.
(14)
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The probabilistic formulation of the tensor model allows inference involving all of these data
types to be conducted using Markov Chain Monte Carlo (MCMC). In particular, appropriate
prior distributions on the model parameters lead to an efficient Gibbs sampling algorithm
for sampling from the posterior distribution of the model parameters given the tensor data.
Missing entries—a common feature of large genomics datasets—can be assumed Missing at
Random (MAR) and marginalized out of the model within the Gibbs steps (see Section 1.3
of the Appendix).
Closer examination of the normal tensor model reveals a connection to the linking
model in (6). Recall the vectorization-Kronecker identity vec(ABC>) = (C ⊗ A)vec(B)
where vec is defined as the operator that stacks the columns of an m × n matrix to form
an m · n × 1 column vector (Horn and Johnson, 2008). Ignoring the intercept term µk for
notational convenience and applying this identity to the tensor model yields a vectorized
representation:
vec(Θk)|Bk,U,V, τ 2k ∼ NGL
(
(V ⊗U)vec(Bk), τ 2k IGL
)
. (15)
Now suppose that the model parameters U and V have been estimated from tensor data
measuring biological effects from several genomics modalities. From the point of view of an
experimenter running a hypothesis-driven experiment using a new modality k′, the matrix
V ⊗U represents historical information about the associations among cancer cell lines and
among genes. According to (6), the linking model for biological effects measured by the new
modality is
θk′ |βk′ ∼ NGL(Xβk′ , τ 2k′IGL). (16)
Replacing X with V⊗U, βk′ with vec(Bk′), and θk′ with vec(Θk′) in the above reveals that
the linking model (6) is just a special case of (15) for a new modality k′.
Hence, for experimental data from a hypothesis-driven study, FAB tests and FAB p-
values based on this linking model can be constructed by first estimating U and V from the
tensor probability model, then testing each biological hypothesis Hj by setting X = V ⊗U
and following the procedure in Section 2.1 using the subset of the rows of X that correspond
to the effects θlgk′ measured in the new study (Figure 1). The first step is computationally
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intensive, but need only be run once in advance of seeing new experimental data. The second
step requires a computation for each hypothesis in the new study, but can be done efficiently
using linear algebraic results for leave-one-out estimation. See Sections A.1 and A.2 of the
Appendix for details on this two-step procedure.
Θ
Θk′ 
Bk′ 
B
U
V⊤l
g
θlgk′ ≈ U⊤l Bk′ Vg
= (Ul⊗ Vg)⊤
= X⊤lg
Y¯lgk′ ≃ θlgk′ ≈ X⊤lgβk′ 
βk′ 
βk′ 
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≈ × ×
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Figure 1: Schematic of the FAB testing procedure. Cancer cell line and gene historical
information profiles distilled from the tensor Θ are used to model biological effects from a
new modality. Experimental replicates from the new modality are assumed to be iid normal
samples from the biological effects.
3 Results
The procedure described above was applied to several simulated and real datasets to validate
its type I error control, its robustness to irrelevant historical information, and its ability to
yield more discoveries on real genomics data. The cancer cell line and gene features derived
from the tensor probability model allowed the FAB testing procedure to be applied to mea-
surement types as diverse as CRISPR dependency scores, drug viability profiles, differential
expression scores from mammary cell subpopulations, and differential CRISPR dependency
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scores between mutant and wild-type cells. Though the assumed sampling model in (5) ap-
plies to experimental data with heteroscedastic error structure, in the simulation studies and
investigations with real genomics data, a common sampling variance was assumed, so that
σ2j = σ
2 for all j = 1, . . . ,M . In all cases the independent estimators σˆ2, σ˜2 were calculated
using an appropriate data-partitioning strategy on the entries of S (see Section A.1 of the
Appendix).
3.1 Simulation studies
To verify that the FAB procedure produces uniformly distributed p-values under the null
hypothesis, 10, 000 datasets were simulated, each consisting of vectors Y¯,S of length 250.
Each entry of Y¯ and S was calculated from 5 samples drawn from a N(0, 1) distribution,
representing 5 replicates of a null measurement with sampling variance equal to 1. Matrices
U ∈ R10×5,V ∈ R25×5, representing, respectively, cancer cell line and gene features were then
generated with entries drawn from N(0, 1). The distribution of FAB p-values obtained from
fitting models (5), (6) to each of the 10, 000 datasets was empirically uniform, indistinguish-
able from that of the classical p-values (Figure 2). To demonstrate proper FDR control, the
p-values obtained for each dataset were then adjusted using the Benjamini-Hochberg (BH)
procedure (Benjamini and Hochberg, 1995). Since all of the values in each of the datasets
were simulated from null effects, a value of 1 was recorded for a dataset if any of its BH-
adjusted p-values fell below a target of 0.1. A value of 0 was recorded otherwise. Taking the
average of the 0’s and 1’s over the 10, 000 trials yielded Monte Carlo estimates of the FDR
for the classical and FAB tests. Both achieved the target FDR of 0.1 up to Monte Carlo
error (Figure 2).
Further simulations were conducted to test the behavior of the FAB procedure under
non-null scenarios. First, matrices U ∈ R5×10,V ∈ R100×10 were generated with entries
drawn from N(0, 1) and a matrix X was set to X := V⊗U. Then, vectors β ∈ R100,  ∈ R500
were generated, each with entries drawn from N(0, 1). The vectors Xβ and  were then
normalized to have empirical variance equal to 1. For τ 2—the magnitude of variation left
unexplained by X—taking values in {1, 0.8, 0.6, 0.4, 0.2, 0}, a biological effects vector was
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Figure 2: Results of a simulation study on 10000 simulated datasets, each consisting of 10
cell lines, 25 genes, and 5 replicates. Each dataset was generated from the null sampling
model (θ = 0) with σ2 = 1. The left plot shows the distribution of p-values from a two-sided
t-test. The middle plot shows the distribution of FAB p-values. The right plot shows the
Monte Carlo average of the FDR with errorbars giving ± 1 Monte Carlo standard error.
Both procedures achieve the target FDR of 0.1.
constructed according to
θ =
√
1− τ 2Xβ +
√
τ 2
and 200 datasets Y¯,S were simulated for each value of τ 2 according to Yij ∼ N(θj, 1), i =
1, . . . , 5. The simulation procedure therefore ensured that the total variation in θ was held
constant at 1, while the proportion of variation explained by X increased as τ 2 decreased.
The cumulative number of discoveries made across the 200 trials was then recorded at varying
FDR thresholds. As shown in Figure 3, when τ 2 = 1, the FAB procedure yielded as many
discoveries as the classical two-sided test. However, under all other conditions, the FAB test
produced more discoveries at every FDR threshold. As τ 2 decreased the number of discoveries
made by the FAB test cleanly interpolated between that of the classical two-sided test and
that of a one-sided oracle test against the alternative in the direction of sign(θj).
3.2 Smaller p-values in genomics studies
To extract biologically meaningful historical information, the tensor factorization method
described in Section 2.3 was applied to a collection of four genomics datasets downloaded
from the Cancer Dependency Map portal (DepMap, 2019). Each dataset contains the results
of a different screening technology used to measure genetic attributes of a set of cancer cell
lines. The gene expression dataset (Barretina and others , 2012) contains measurements
14
010000
20000
30000
40000
50000
0.
00
1
0.
00
5
0.
01
0.
05 0.
1
FDR
# 
of
 d
isc
ov
e
rie
s
Test
UMPU
FAB
OS
 τ2  =  1
0
10000
20000
30000
40000
0.
00
1
0.
00
5
0.
01
0.
05 0.
1
FDR
# 
of
 d
isc
ov
e
rie
s
 τ2  =  0.8
0
10000
20000
30000
40000
0.
00
1
0.
00
5
0.
01
0.
05 0.
1
FDR
# 
of
 d
isc
ov
e
rie
s
 τ2  =  0.6
0
10000
20000
30000
40000
0.
00
1
0.
00
5
0.
01
0.
05 0.
1
FDR
# 
of
 d
isc
ov
e
rie
s
 τ2  =  0.4
0
10000
20000
30000
40000
50000
0.
00
1
0.
00
5
0.
01
0.
05 0.
1
FDR
# 
of
 d
isc
ov
e
rie
s
 τ2  =  0.2
0
10000
20000
30000
40000
50000
0.
00
1
0.
00
5
0.
01
0.
05 0.
1
FDR
# 
of
 d
isc
ov
e
rie
s
 τ2  =  0
Figure 3: Results of a simulation study demonstrating the effect of increasing model precision
on the behavior of the FAB test. The plot titles show the proportion of variance in θ
unexplained by X. The height of the bars represent the cumulative number of discoveries
made at increasing FDR levels for two-sided classical (light blue), FAB (yellow), and one-
sided oracle (dark grey) tests. When the lack-of-fit variance τ 2 is close to the total variance
in the biological effects, the FAB test yields as many discoveries as the standard two-sided
test. When τ 2 is small, the FAB test behaves more like a one-sided oracle test.
of mRNA abundance, which is a proxy for the amount of the gene-product active in the
cell. The mutation dataset (Barretina and others , 2012) contains binary entries indicating
whether gene g is mutated in cell line l. The CRISPR (Meyers and others , 2017) and RNAi
(McFarland and others , 2018) datasets each contain cell viability scores corresponding to the
growth inhibitory effect induced in cell line l when gene g is deleted (CRISPR) or suppressed
(RNAi).
The tensor probability model was fit to these four modalities using the tobit model
(14) for the gene expression dataset, the probit model (13) for the mutation dataset, and
the normal model (11) for the CRISPR and RNAi datasets. Historical information profiles
of dimension dU = 16 and dV = 64 were distilled for 1209 cancer cell lines and 4570 genes,
respectively (Section A.5 of the Appendix). Appropriate prior distributions on the tensor
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model parameters yielded closed form conditional probability densities, which were used to
obtain 5, 000 samples from the posterior distributions of all model parameters via a Gibbs
sampling algorithm (Section A.3 of the Appendix). The first 1, 000 samples were discarded,
and estimators of the cancer cell line and gene historical information profiles were obtained
by taking the average of the remaining 4, 000 posterior samples of U and V after aligning
them with a Procrustes procedure (Section A.4 of the Appendix). Subsets of the matrix
X = V ⊗U were then used as predictors in the linking model (6) to perform FAB tests for
hypotheses in several genomics studies.
3.2.1 CRISPR essentiality screens in human AML cell lines
To demonstrate the utility of the FAB testing framework on genomic screening modalities
already contained in the Dependency Map collection, dependency scores for 11 acute myeloid
leukemia (AML) cancer cell lines and 3537 genes were obtained from genome-wide CRISPR
screens conducted by Wang and others (2017). The results of applying the FAB testing
procedure using the corresponding cancer cell line and gene historical features are displayed
in Figure 4. As shown, the FAB test produced more discoveries than the standard two-sided
test at a range of FDR levels. The observed increase in power was a result of the relatively
high degree of predictive model fit (Figure 4, bottom row). Many of the AML cell lines in
the Wang and others (2017) dataset were also screened with the CRISPR technology by
DepMap (2019); hence, it is reassuring though perhaps not surprising that the model had
good predictive performance on the data corresponding to these cell lines (Figure 4, bottom
left). Of note is the fact that the model also showed good predictive performance on the
3 cell lines not screened as part of the Dependency Map CRISPR effort (Figure 4, bottom
right). For these cell lines, the information pertaining to CRISPR dependency was truly
indirect, coming from other cancer cell lines and other modalities in the Dependency Map
collection.
3.2.2 Viability profiling to repurpose non-oncology drugs
The use of historical information distilled from the Dependency Map need not be limited to
experimental designs with many cell lines and many genes. The FAB testing procedure is also
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Figure 4: Results of applying the linear model to data from the Wang and others (2017)
CRISPR essentiality screens. In the upper left plot, the number of discoveries at an FDR
of 0.1 is plotted for each test. In the upper right plot, BH-adjusted p-values for standard
two-sided and FAB tests are plotted against the rank of the adjusted p-value. The FAB
test leads to more discoveries for a range of FDRs. The lower plots show predicted CRISPR
dependency scores against observed CRISPR dependency scores for cell lines that also appear
in the DepMap CRISPR dataset (left) and those that do not (right).
applicable to a class of experiments known as “cell viability profiling” in which a perturbagen,
such as a drug, is applied to a panel of cell lines in order to determine which cell lines are
sensitive or resistant to the perturbagen’s action. Negative viability scores correspond to cell-
death or growth-inhibition in response to the drug treatment, while positive scores suggest
enhanced proliferation. A recent effort to uncover oncology indications for non-oncology
drugs (Corsello and others , 2019) produced 4686 such viability profiles, each corresponding
to a drug’s action on a panel of 578 cancer cell lines, 569 of which appear in the Dependency
Map dataset. For these experiments, the cell line features were used to model each of the
drug viability profiles. Using the notation from Section 2.3, the procedure was equivalent
to setting V := 1. As shown in Figure 5, at an FDR of 0.1, the FAB tests yielded as many
17
or more discoveries than traditional p-values for 80% of the drugs screened. For 67% of the
drugs screened, the FAB test yielded strictly more discoveries. As measured by absolute
deviance from the red line on the main diagonal of Figure 5, the difference between the
number of discoveries made by the FAB and classical tests tended to be small when the
FAB test yielded fewer discoveries and tended to be larger when the FAB test yielded more
discoveries.
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
0
200
400
0 200 400
Number of Discoveries UMPU
N
um
be
r o
f D
isc
ov
e
rie
s 
FA
B
l
l
l
More discoveries
Equal discoveries
Fewer discoveries
Figure 5: Number of discoveries made at an FDR of 0.1 for each compound profile in
Repurposing dataset for classical and FAB p-values. Drugs for which more discoveries were
made by the FAB test are highlighted in yellow, while drugs for which more discoveries were
made by the classical test are highlighted in blue. Drugs for which the number of discoveries
was equal are highlighted grey and lie along the red diagonal line.
3.2.3 Differential expression analysis for mammary cell subpopulations
Experimental data containing measurements for hundreds of cancer cell lines are relatively
scarce due to the labour-intensive nature of cell culture. More common in the genomics
literature are datasets with treatment-control measurements for a limited number of samples,
but many genes. These data are often interpreted by performing a differential expression
analysis, in which significant genes are identified by conducting hypothesis tests on contrast
scores between samples in the treatment and control conditions for each gene in a study.
To demonstrate the utility of the FAB procedure in differential expression analysis,
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gene expression profiles of mammary cell subpopulations from three healthy human donors
were obtained from a study conducted by Lim and others (2009). Each donor in the study
contributed samples of mammary stem cells (MS), luminal progenitor cells (LP) and ma-
ture luminal cells (ML). The object of the study was to test for significantly differentially
expressed genes between MS / LP, MS / ML, and ML / LP cell populations. To prepare
the data for use, the steps outlined in the tutorial for the software package limma (Ritchie
and others , 2015, 2007; Smyth and Speed, 2003) were followed. For each contrast, the
FAB testing model was applied to the average difference in gene expression between the cell
populations, using the gene features V.
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Figure 6: Results of applying the linear model to data from Lim and others (2009). From
left to right, the contrasts tested were MS vs. LP, MS vs. ML, and ML vs. LP. Although
the model precision is far from perfect (bottom row), the FAB test is more powerful at an
FDR of 0.1 for all three contrasts.
Although the linking model precision varied across the different contrasts, it showed
some capacity for predicting all of the differential expression scores (Figure 6). Correspond-
ingly, the FAB p-values yielded more discoveries at an FDR of 0.1 for each of the three
contrasts than those from a traditional two-sided t-test. The fact that the FAB approach
was able to achieve some predictive power in this setting is notable for two important rea-
sons: first, it suggests that the FAB framework can be applied to modalities—such as contrast
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scores—that bear very little relationship to those contained in the dataset from which the
historical information was distilled. Second, it suggests that the gene-to-gene relationships
distilled by the tensor model from a corpus of cancer genomics data generalize to non-cancer
biological contexts.
3.2.4 Robustness of the FAB test
The FAB testing procedure convincingly yields more discoveries than the classical two-sided
test when applied to experimental data with some degree of linear relationship to historical
features. To illustrate what happens in practice when there is little to no linear relationship
between the historical features and the experimental data, CRISPR dependency scores from
the Kory and others (2018) study were obtained for 2 cancer cell lines and 2865 genes.
The dependency scores consist of measurements for each cell line under two experimental
conditions: culture in media that contained the α-amino acid serine, and culture in serine-
free media. Differential dependency scores were calculated by taking the difference in average
dependency score between the culture conditions.
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Figure 7: Results of applying the linear model to data from the Kory and others (2018)
study. The model predictions are uncorrelated with the observed differential dependency
scores (left). Still, at an FDR of 0.1 relatively few discoveries are made only by the classical
test (center, blue), while relatively many are made only by the FAB test (center, yellow).
Moreover, the list of top 1-100 most significant genes within each cancer cell line for the FAB
and classical tests are nearly identical to one another (right).
In contrast to previous examples, the differential dependency scores predicted by the
linking model showed almost no correlation to the observed data from this study (Figure 7,
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left). The FAB test yielded more discoveries than the classical test, but the increase in power
was due to the fact that most of the observed differential dependency scores had positive
values. Hence the predicted values from the linking model were centered about a positive
intercept term. However, the scale of the predicted values was appropriately small relative
to that of the observed data due to the shrinkage induced by the empirical Bayes estimator
ψ˜2. Likewise, the estimator τ˜ 2 was appropriately large, so that the computed offset terms
bFABj were conservative relative to the classical test statistics Tj. The result was that, at an
FDR of 0.1, relatively few discoveries were made only by the classical test, while relatively
many discoveries were made only by the FAB test (Figure 7, middle). For both cancer cell
lines in the study, the lists of genes produced by taking, respectively, the r-smallest adjusted
classical and FAB p-values also showed a high degree of overlap for ranks r = 1, . . . , 100
(Figure 7, right).
3.2.5 Biological relevance of FAB discoveries
While the FAB testing procedure has the potential to increase the expected number of
discoveries made in a given study, it does not give any guarantees about the quality of
those discoveries. The latter is difficult to analyze in the abstract. In practice, however, the
quality of additional discoveries in genomics studies may be analyzed by evaluating their
biological plausibility. To this end, FAB tests were performed in a differential dependency
analysis between 10 Ras-mutant and 8 Ras-wild-type AML cell lines using data from a follow-
up experiment conducted by Wang and others (2017). The follow-up experiment measured
CRISPR dependency scores for a focused set of 127 genes. Some of the genes were previously
suspected to be interactors with oncogenic Ras and others were included as controls. The
discoveries made by the FAB and classical tests at an FDR of 0.1 are highlighted in Figure
8.
Overall, the FAB test yielded 30 discoveries, compared to 23 discoveries from the
classical test. Among the genes discovered only by the FAB test was NRAS, a member of
the Ras family and one of the genes used to distinguish Ras-mutants from wild-type. Ras-
mutant cancer cell lines tend to show increased dependency in Ras family genes (note that
the oncogene KRAS is one of the primary discoveries made by both tests) compared to wild-
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Figure 8: Results of applying the linear model to data from the follow-up study in Wang
and others (2017). The genes discovered at a 0.1 FDR threshold are displayed above for the
FAB test and below for the classical test.
type cancer cell lines, so the inclusion of NRAS among the list of discoveries is biologically
plausible. Another discovered gene, ICMT, was a hit in a separate experiment from the Wang
and others (2017) article and is known to be involved in the maturation of Ras. Yet another
gene discovered by the FAB test alone, ELAVL1, is a putative regulator of cell survival
in KRAS-driven pancreatic ductal adenocarcinomas (PDACs) (Brody and Dixon, 2018),
though its role in the context of AML is not as well understood. Finally, the gene ELOVL1,
discovered only by the FAB test, is a fatty acid elongase that performs cell-essential fatty acid
synthesis. It has been reported that Ras-driven tumors activate fatty acid synthesis genes,
and that this activation creates a synthetic lethality with Rapamycin (Gouw and others ,
2017; Salloum and others , 2014). Further, Guo and others (2016) note that Rapamycin
supresses expression of ELOVL1 in bovine mammary epithelial cells (BMECs). Hence, loss-
of-function of ELOVL1 could plausibly have a differentially adverse effect on Ras-mutant
cancer cell lines like those in the Wang and others (2017) follow-up study. Together, these
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results suggest that the additional genes discovered by the FAB test are likely from the set
of biologically relevant Ras-interactors, rather than from the set of inactive controls.
4 Discussion
Given a sufficiently rich source of historical information, hypothesis tests in genomics studies
can realize substantial gains in statistical power under the FAB testing framework while still
maintaining experiment-wise type I error rates. A probability model that describes rela-
tionships among biological effects can be used not only to synthesize this source of indirect
information, but also to construct a distribution according to which FAB p-values are com-
puted. Regardless of whether this probability model is correct, however, the resulting FAB
p-values are uniformly distributed under the null hypothesis. In the case of model misspec-
ification, parameters that inform the degree to which historical information is relevant to a
given genomics study can be estimated via an empirical Bayes strategy in order to protect
against over-confidence in inferred quantities used in the FAB tests. Both in simulation and
in practice, this procedure adaptively reverts FAB tests to classical tests, so that bona fide
discoveries are not obscured when the model fit is poor. This suggests that the FAB testing
framework can safely be applied even when the relevance of the historical information to data
from a new study is unknown. Practical investigations demonstrate that historical features
distilled from the Cancer Dependency Map dataset by the tensor probability model contain
information relevant to data types ranging from direct readouts of familiar screening tech-
nologies to esoteric contrast scores between distinct, non-cancerous biological populations.
A promising research direction is to consider whether there are other ways in which these
features might be used to inform practitioners of hypothesis-driven genomics experiments.
5 Software
Software in the form of R code is available at https://github.com/j-g-b/BTF.
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A Appendix
A.1 Empirical Bayes estimation of variance parameters
A.1.1 Data partitioning
The empirical Bayes strategy for estimation of the relevance of the historical data is as
follows: first, estimate σ˜2. Then obtain estimators of τ 2, ψ2 by maximizing the marginal
likelihood of the data under the assumption that σ2j = σ˜
2 for j = 1, . . . ,M . The assumption
of homoscedasticity eases the computations involved with evaluating the marginal likelihood
of the data, as explained below. However, it should be noted that this assumption applies
only to the sampling model assumed when calculating the value for bFABj , not the (possibly)
heteroscedastic sampling model that underlies the validity of the FAB and classical hypothe-
sis tests. The FAB test is valid as long as bFABj is statistically independent of the test statistic
Tj.
The independence of bFABj and Tj can be accomplished by partitioning the available
data into two non-overlapping index sets. Let J be an index set containing a randomly
selected half of the entries in {1, . . . ,M}. Then let
σ˜2 =
∑
j∈J
(
S2j /ν˜
)
(nj − 1) (17)
where ν˜ =
∑
j∈J (nj − 1). Given σ˜2 corresponding to the index set J , estimators τ˜ 2 and ψ˜2
can be found by maximizing the marginal likelihood of the data Y¯j, j ∈ J induced by the
combined sampling model, linking model, and hierarchical prior on the coefficients β (see
the following section). For Y¯j, j /∈ J , estimators σˆ2j can be computed from entries Sj where
j /∈ J such that under the null hypothesis Hj : θj = 0, the statistic Tj = Y¯j/
√
σˆ2j/nj is
distributed as a tνˆ random variable. Hence, any b
FAB
j , computed from σ˜
2, τ˜ 2, and ψ˜2 using
data Y¯j, Sj, j ∈ J is independent of any Tj where j /∈ J , and vice versa.
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A.1.2 Maximizing the marginal data likelihood
Consider the sampling and linking model with the normal hierarchical prior distribution on
β as in the main text
Y¯|θ ∼ NM(θ, diag(σ21/n1, . . . , σ2M/nM))
θ|β ∼ NM(Xβ, τ 2IM)
β ∼ Nq(0, ψ2Iq)
(18)
Under this model, the induced marginal density on Y¯ is
p(Y¯) =
1√
2pi|A| exp
(
−Y¯
>A−1Y¯
2
)
(19)
where the marginal covariance of Y¯ is
A = ψ2XX> + τ 2IM + diag(σ21/n1, . . . , σ
2
M/nM) (20)
As long as the rows of X are not mutually orthogonal—which would make XX> equal to
the identity—variation due to ψ2 and variation due to τ 2 can be disambiguated. In fact,
given values for the σ2j , maximum likelihood estimators for ψ
2 and τ 2 are available, even
when p > n.
The log-likelihood of ψ2 and τ 2 under the marginal density for Y¯ is
`(τ 2, ψ2) = −1
2
(
log 2pi + log |A|+ Y¯>A−1Y¯) (21)
The maximizer of `(τ 2, ψ2) is not available in closed form. In addition, numerical opti-
mization applied to the expression above requires computing the M ×M matrix A, which
can become very large when the number of hypotheses is large. Making the approxima-
tion σ˜2/nj ≈ σ˜2/n¯ for j = 1, . . . ,M eases much of this computational burden. Letting
XX> = QΛQ> be the orthogonal eigendecomposition of the symmetric matrix XX>, A
can now be written as
A = Q(τ 2IM + ψ
2Λ + (σ˜2/n¯)IM)Q
> (22)
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from which it is clear that the eigenvalues of A are
τ 2 + ψ2λj + σ˜
2/n¯, j = 1, . . . ,M (23)
where λi is the i
th eigenvalue of X. The first q eigenvectors of XX> can be obtained by
taking the singular value decomposition of X. If q ≥ M , then these are all that is needed
to evaluate the log-likelihood. If q < M , then the M − q remaining eigenvectors do not
need to be computed explicitly. Since the columns of Q form an orthonormal eigenbasis
for RM , these eigenvectors correspond to the directions that are orthogonal to the first
q eigenvectors of XX>. In addition, the associated eigenvalues of these directions are 0.
Hence, the component of the quadratic form Y¯A−1Y¯ corresponding to these directions has
total norm
||Y¯||22 −
∑q
j=1 ||Q>j Y¯||22
τ 2 + σ˜2/n¯
. (24)
The maximum likelihood estimators for τ 2, ψ2 are thus found by numerically finding τ 2, ψ2
that maximize
−
q∑
j=1
[
log(τ 2 + ψ2λj + σ˜
2/n¯) +
||Q>j Y¯||22
τ 2 + ψ2λj + σ˜2/n¯
]
− I[q < M ] ||Y¯||
2
2 −
∑q
j=1 ||Q>j Y¯||22
τ 2 + σ˜2/n¯
(25)
Finally, note that the Kronecker structure of X specific to the tensor model described in
the main text can be exploited to calculate the eigenvalues and eigenvectors of XX> by
computing the singular value decompositions of U and V.
A.2 Result for leave-one-out estimation
The following result uses linear algebra identities to obtain expressions for the leave-one-out
(LOO) estimators
m˜j = X
>
j G
−1
−jX
>
−jY¯−j v˜j =
(
Wjj
Wjj + τ 2
)2
X>j G
−1
−jXj + τ
2. (26)
The LOO estimators can be written in terms of the corresponding estimators based on the
full model. The LOO estimators corresponding to the rows of a matrix can therefore be
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calculated with only one matrix inversion operation on the q × q matrix used to fit the full
model. Recall from the main text that G = X>HX + (1/ψ2)Iq and note that
X>HX + (1/ψ2)Iq =
M∑
j=1
HjjXjX
>
j + (1/ψ
2)Iq (27)
so
G−1−j =
(
X>−jH−jX−j + (1/ψ
2)Iq
)−1
=
(
X>HX + (1/ψ2)Iq −HjjXjX>j
)−1
.
(28)
From here, use the Woodbury matrix inversion identity to obtain
G−1−j = G
−1 +
(
Hjj
1−HjjX>j G−1Xj
)
G−1XjX>j G
−1. (29)
Hence,
m˜j = X
>
j G
−1
−jX
>
−jY¯−j
= X>j (G
−1
−jX
>HY¯ −G−1−jXjHjjY¯j)
(30)
Substituting 29 into 30 and simplifying yields
m˜j = θ˜j −
HjjX
>
j G
−1Xj
1−HjjX>j G−1Xj
(Y¯j − θ˜j) (31)
where θ˜j = X
>
j G
−1X>Y¯. Performing a similar substitution into the expression for v˜j yields
v˜j =
(
Wjj
Wjj + τ 2
)2 HjjX>j G−1Xj
1−HjjX>j G−1Xj
+ τ 2 (32)
A.3 Inference and Gibbs sampling in the tensor probability model
A priori, it is assumed that the cell line representations Ul are independently distributed as
NdU (0, I) and the gene representations Vg are independently distributed as NdV (0, I). The
matrices Bk are vectorized and the vec(Bk) are given independent flat priors NdU×dV (0,∞I).
Finally, it is assumed that each precision variable 1/τ 2k is drawn independently fromG(1/2, 1/2)
and each µk is drawn independently from N(0, 1).
A Gibbs sampling algorithm is used to obtain samples from the posterior distribution
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of the parameters in the tensor probability model. In each Gibbs step, the cell line features
are sampled using the full conditional distribution
Ul|Θ,V,B, τ 2 ∼ NdU
(
η∗l , [Λ
∗
l ]
−1) (33)
with
Λ∗l = I +
∑
g,k
(1/τ 2k )BkVgVg
>Bk>
η∗i = [Λ
∗
l ]
−1
(∑
g,k
(1/τ 2k )(θlgk − µk)BkVg
)
.
(34)
Analogous expressions are used to update the gene features Vg. The each vec(Bk) is sampled
from the conditional distribution
vec(Bk)|Θ,U,V, τ 2 ∼ NdV ×dU
(
ξ∗k, [Ψ
∗
k]
−1)
Ψ∗k = (1/τ
2
k )
∑
i,j
[(
VgVg
>)⊗ (UlUl>)]
ξ∗k = [Ψ
∗
k]
−1
(
(1/τ 2k )
∑
l,g
(θlgk − µk)(Vg ⊗Ul)
)
.
(35)
Finally, τ 2k is sampled according to
1/τ 2k |Θ,U,V,B ∼ G (a∗k, b∗k)
a∗k =
NM + 1
2
b∗k =
∑
l,g
[
θlgk − µk −Ul>BkVg
]2
+ 1
2
(36)
and µk according to
µk|Θ,U,V,B, τ 2k ∼ N
(
γ∗k, [φ
∗
k]
−1)
γ∗k = [φ
∗
k]
−1
(∑
i,j
(1/τ 2k )(θlgk −U>l BkVg)
)
φ∗k = (NM/τ
2
k ) + 1
(37)
Inference for the biological effects θlgk proceeds as follows: for a modality k with data
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modeled with the normal sampling model, θlgk = Ylgk at each Gibbs iteration. For a modality
k with binary data, the θlgk have full conditional distributions given by
θlgk′|Y,U,V,B ∼

N+(µk′ + U
>
l Bk′Vg, 1) if Ylgk′ = 1
N−(µk′ + U>l Bk′Vg, 1) if Ylgk′ = 0
(38)
where N± denotes the normal distribution truncated from below and above, respectively,
at 0. For a modality k with strictly positive continuous data, the θlgk have full conditional
distributions
θlgk|Y,U,V,B, τ 2k ∼

Ylgk if Ylgk > 0
N−(µk + U>l BkVg, τ
2
k ) if Ylgk = 0
(39)
Missingness in large genomics corpora often has to do with availability of cell line
samples or sequencing library size. Therefore, it is reasonable to assume that missing data
are missing at random (MAR). Under a MAR assumption, marginalizing out missing data is
accomplished by treating the missing data like model parameters within the Gibbs sampling
steps: at each iteration, a new Ylgk is drawn according to its sampling model given the other
model parameters. For the normal model, this means Ylgk is drawn from
Ylgk|U,V,B, τ 2k ∼ N(µk + U>l BkVg, τ 2k ). (40)
In the probit model, Ylgk is drawn from
Ylgk|U,V,B, τ 2k ∼ B(Φ(µk + U>l BkVg)) (41)
and in the tobit model Ylgk is drawn from
Ylgk|U,V,B, τ 2k ∼ N+(µk + U>l BkVg, τ 2k ) (42)
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A.4 Identifiability and Procrustes alignment
The parameters U,B,V in the tensor factorization model are not identifiable, since for any
square orthogonal matrices Q,P and diagonal scaling matrices L,J the following holds
UBkV
> = ULQ>QL−1BkJ−1P>PJV> (43)
In MCMC sampling algorithms, like Gibbs sampling, it is common to observe that such
rotation and scale ambiguity leads to misalignment of samples from disparate parts of the
Markov Chain. Hence, before taking posterior summaries, it is necessary to align the samples
of the matrices U,B and V to a common rotation and scale. This is accomplished by
a Procrustes alignment procedure, followed by a scaling of each of the aligned U and V
samples to have unit column norm. The scaling and rotation operations applied to each
sample of U and V are then passed to the samples of Bk, so that the overall matrix product
is preserved—that is, if U∗, V∗, and B∗k are the aligned counterparts to U, V and Bk, then
U∗B∗kV
∗> = UBkV> (44)
for every sample.
A.5 Choice of cancer cell lines and genes for inclusion in tensor
probability model
Cancer cell line historical feature profiles were inferred for all cancer cell lines that appeared
in at least one of the four cancer genomics datasets from the Dependency Map collection.
This totaled 1209 cancer cell lines. The list of genes for which historical information profiles
were derived was obtained by taking the union of the following sets of genes: (1) genes in the
COSMIC cancer gene census (Sondka and others , 2018), (2) genes in the Kory and others
(2018) study, (3) genes in the Wang and others (2017) focused screen, (4) the top 1, 000
genes as ranked by variance of gene expression profile, and (5) the top 1, 000 genes as ranked
by sum of squared gene expression values. In total, this list contained 4570 genes.
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